Skip to main content

The future of neuroscience drug development

Despite several pullbacks in the field in the last decade, there are signs neurology is again a priority in some corners of the industry. Biotech companies have drawn big-name backers as they’ve moved promising brain drugs into late-stage testing, and new medicines for Alzheimer’s, ALS and depression show a path to market.

included in this trendline
  • Neuro-focused biotech Neumora prices IPO in sign of investor interest
  • Big pharma backed away from brain drugs. Is a return in sight?
  • Why the FDA cleared Amylyx’s drug Relyvrio for ALS
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.